GMZP-Why is it suddently trading again? 3 blocks of almost 10 million each traded on Friday. Why? No news about it. Does anyone know?

Anybody want to see a blog by an overseas consumer who tried this product, Nansulate? I found it recently. He started out angry, as there was a long delay while waiting for product... he started to think he'd been duped.

Then it finally arrived, and he started to apply it to his house... and low and behold, he was amazed. This stuff IS amazing.

The change in his attitude is impressive, and he gives some pretty amazing temperature stats in a recent blog entry:

http://lignieres.blogspot.com/

I just noticed that this is board #2000.

New millenium technology, nanotech is, so that's appropriate.

Too bad this board is not very active.

Is it time to discuss nanotech stocks again soon?

Just a FYI, INTK is getting quite a bit of seemingly credible 3rd party press (trade magazines, 2008 best product awards, etc) lately. I saw INTK on the stock list for this board, so I thought I'd make a post here today.

It's a patented line of thin, clear, coatings which insulate very well, prevent corrosion, and prevent mold. Oh, and encapsulate lead as well. It can be applied to homes, or pipes/tanks (or any surface), and is also used in industry.

There are case studies, MSDS, product spec sheets, application tips, list of projects (both industrial and residential), etc, etc, on their website. It's pretty interesting.

http://www.nansulate.com/index.html

p.s. I've tried it personally, and it does seem to work as claimed.

Battelle Ventures Invests in BioNanomatrix, Leading the DNA-Analysis Company's $5.1-million Series A Funding Round

Last update: 3/26/2008 8:05:01 AM

PRINCETON, N.J., Mar 26, 2008 (BUSINESS WIRE) -- Battelle Ventures, LP, has led the $5.1-million Series A funding round of BioNanomatrix, Inc., a Philadelphia-based company developing and commercializing nanoscale, single-molecule imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome.

The round was joined by Battelle Ventures' affiliate fund, Innovation Valley Partners, and by KT Venture Group (the investment partner of KLA-Tencor).

Seed investors Ben Franklin Technology Partners and 21Ventures also participated in the financing, through debt conversion.

"By applying its nanotechnology-based, single-molecule detection capabilities to the development of innovative products for genetic analysis and clinical diagnostics, BioNanomatrix has the potential to successfully commercialize a truly disruptive technology - one that could significantly reduce the time, complexity and cost dynamics of sequencing the genome and carrying out genetic analyses," said Battelle Ventures General Partner Tracy Warren.

"Today, the high cost and complexity of obtaining and analyzing these data have greatly limited their broad utility for gene discovery, clinical diagnostics and pharmaceutical research and development, as well as for applying individual genomic data to disease prevention, diagnosis and treatment," she continued.

"We believe that the breakthrough BioNanomatrix technology has the potential to fundamentally change the current marketplace dynamic, enabling widespread adoption of genomics-based medicine," she said.

"BioNanomatrix's whole genome imaging and analysis technology enables nanoscale identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel, high-throughput format," explained BioNanomatrix CEO Michael Boyce-Jacino.

"We are developing analytic platforms based on this technology that will rapidly and cost-effectively provide ultra-high-resolution analyses of genomic, epigenomic and proteomic information."

Dr. Boyce-Jacino noted that the company has received several federal product-development grants and also is collaborating with a leading global life sciences firm to apply its analytic technology for near-term R&D applications.

"The most exciting application for BioNanomatrix's technology, though, may be its potential to dramatically slash the cost of whole genome sequencing and analysis," said Warren. "The marketplace has been clamoring for significant reductions in genome sequencing and analysis costs, with such publicly declared targets as the $1,000 genome," she said.

"But BioNanomatrix has the potential to significantly leapfrog these ambitious cost goals, targeting a system that can sequence the genome in eight hours at a cost of just $100."

Warren noted that BioNanomatrix was recently awarded an $8.8-million federal grant with its collaborator Complete Genomics, Inc., to develop a system capable of producing the $100 genome.

"Achieving this combination of speed, accuracy and cost reduction could transform the use of genomic analysis," she continued, "making it a practical vehicle for a widely expanded range of applications."

"BioNanomatrix's nanoscale technologies make possible the cost-efficient manufacture of nanochips that are compatible with off-the-shelf optics," explained Dr. Boyce-Jacino, "allowing the company to develop advanced analytic systems at a moderate cost."

A key contributor to the company's advanced technology is its proprietary chips, he said.

"Their tiny nanochannels make it possible to individually observe, identify and assess long, intact molecules of DNA, epigenetic markers and other proteins on a single-molecule basis," he said. "At the same time, the technology also is designed to operate in massively parallel formats, allowing for large-scale multiplexing and ultra-high-throughput capacity."

Said Warren, who joins the company's Board of Directors: "The wonderful thing about BioNanomatrix from an early-stage investor's point of view is that, in the short term, the company should have viable commercial products and, in the next few years, it has a compelling potential to play a critical role in the coming transformation of this underserved genomic marketplace."

Also joining the BioNanomatrix Board is Edward L. Erickson, who has extensive experience in the medical products industry, having served as president, CEO or a director of more than a dozen such companies, four of which successfully completed IPOs during his tenure.

About Battelle Ventures and Innovation Valley Partners Battelle Ventures and its Knoxville, Tenn.-based affiliate fund, Innovation Valley Partners (IVP), have a combined $255 million under management to create and accelerate the development of early-stage technology companies with breakthrough solutions to multiple marketplace problems. The funds enjoy unique relationships with the technology transfer offices of six U.S. Department of Energy (DOE) National Laboratories and have established similar associations with a number of university tech transfer and commercialization departments. Battelle Ventures was established in August 2003 with a sole limited partner - Columbus, Ohio-based Battelle Memorial Institute (Battelle), the world's largest nonprofit independent research and development organization, which manages/co-manages six National Laboratories for the U.S. DOE. The $220-million Battelle Ventures fund and the $35-million IVP fund backed by Eastern Tennessee business leaders invest side by side in all deals.

For information about the funds' joint health & life sciences portfolio, go to .

To learn more about BioNanomatrix, go to .

For information about San Jose, Calif.-based KT Venture Group, which identifies, invests in and supports promising start-ups in the semiconductor and related high-technology microelectronics areas, see .

Note: Battelle Ventures and Innovation Valley Partners are registered trademarks of BVP Partners, LLC. The names of other organizations, companies, products or services mentioned herein may be the trademarks of their respective owners.

SOURCE: Battelle Ventures
For Battelle Ventures: Rick Sacks, 973-467-8728
rick@smartpr.netor
For BioNanomatrix: Barbara Lindheim, 212-918-4650
blindheim@biocompartners.com
Copyright Business Wire 2008

Nice article

Taking The NanoPulse -- Happy Nano Year!

5 resolutions that can make or break your 2008.

Wednesday, January 09, 2008
By Scott E. Rickert

It's a powerful motivator, isn't it? The New Year triggers thoughts of improving ourselves, our lives -- and our businesses. This year, I have 5 resolutions that need to push aside the usual suspects on you list. Nanotechnology is crucial to building your bottom line, pushing ahead of the competition, or eliminating the threat of someone leaving you in the dust.

That's not just my opinion. Research organizations of every kind provide testimony to the rapid escalation of nanobusiness. One report suggests over 48% compound annual growth rate through 2010. Wherever you look, nanotechnology is changing the rules -- nanofoods, nano-textiles, semiconductors, optics, displays, energy and health. Even nanotech tools could increase 30% next year. Another report suggests the U.S. nano health care market will show a growth rate of nearly 50% through 2009. Even the National Science Foundation sets nanotechnology at the $1 trillion mark by 2015.

So what are you waiting for? If you're going to capture the value of nanotechnology, start this year. Start today.

Nano-Resolution #1: Target three products for nano-ization in 2008. No more investigation. It's time to start producing. I guarantee your competition is hard at it -- even if you're not. Relax, you don't need a Nobel Laureate on your R&D staff to make it happen. The number of nano-enabled "off-the-shelf" opportunities is staggering. What can you put into practice right now? What can you adapt from another market? There are already billions of dollars invested in nano-enabled textiles. Where could that fit in your current product mix to make a product safer, more attractive, and longer lasting?

Nanocoatings now protect electronics, displays, glass, plastics, and metals. Which of your products could benefit from more durability, chemical resistance, and easy-clean characteristics? Nanotechnology is making foods tastier and longer lasting. It's giving lotions and creams new properties and better shelf life. There's a product improvement or a welcome solution waiting for you. Go find it.

Quite frankly, this is the only resolution that matters -- you've got to get nano in 2008. The other resolutions? Some smart ideas to help you achieve Number One.

Nano-Resolution #2: Make contact with three outside companies for nano-partnering. Have you been reading up on "Open Innovation?" It's a current approach to overcoming the "Not Invented Here" syndrome in so many companies. To me, it's a way to jumpstart your nano-efforts. There are plenty of small to midsize companies out there doing the nanotechnology research you many need to accomplish your transformation. Find them. Make an equitable partnership with them -- not a supplier/vendor contract, a real partnership. Co-develop something. You'll get the best from each other now, and build a relationship that will pay big dividends in the future.

Nano-Resolutions #3: Send 3 staff members to a nanotechnology conference. You need to get your team up to speed with you if you're going to accomplish Resolution #1. You can choose hard-core scientific nanotech events, of course. That's where they'll learn the latest technology and get a view of the horizons of possibility. Or, if you prefer, help your people "cut to the chase" of nanotechnology at work in your own industry. Of course, there are plenty of the obvious choices -- electronics, energy, medicine. But whatever your industry, there's probably already a conference that focuses on nano-innovation in it. Textiles? Yep. Food? Naturally. Automotive? From the battery to the paint job. Just go looking.

Nano-Resolution #4: Visit the nanotechnology labs of your local or regional universities. There are millions and millions of dollars going into university research labs. Someone will make a fortune moving the innovations out of the lab and into the marketplace. Why shouldn't it be you? Help guide a spin-off into a start-up into a moneymaker. Invest money when and where you can. Better yet, invest your experience, street smarts and market know-how. I suspect more start-ups have withered from lack of insight than lack of money.

Nano-Resolution #5: Write your Congressman. As with any young industry, there are plenty of issues to consider. First, funding needs to stay strong. The total investments by Asian governments are virtually the same size as North America's. We need to protect our strength. Take a stand on the Research Competitiveness Act, too. Introduced in 2007, this act is a lifeline for nanotechnology and other high-tech start-ups. It ties tax credits to Research and Experimentation costs, not Research and Sales costs. That's a boon to start-ups that don't have sales yet, but have plenty of costs. And, of course, all of us are concerned about environmental and health matters. Read up on the topic and let reason prevail.

That's the plan. Print it out. Tape it to the wall above your desk. Carry it in your wallet. Post it in the coffee room at the office. This is the year for your company to make the move into nanotechnology. Believe me -- it's the key to a Happy New Year, indeed.

Scott E. Rickert is chief executive of Nanofilm, Ltd., located in Valley View, Ohio. His e-mail address is nanotech@industryweek.com.

Why Nanotechnology?

Emerging technology with $2.6 Trillion in new products by 2015. Source: Lux Research.

Global market for nanotechnology products over $10 Billion in 2006 and to grow to about $25 Billion by 2011. Source: BCC Research.

$135 Billion market in 2007 to be $693 Billion in 2012 and $2.9 Trillion in 2015. Source: Cientifica Ltd.

"Next frontier of innovation across almost every sector is based on nanotechnology." Sean Murdock, Executive Director of Nano-Business Alliance

"Nanotechnoly development time is less than half that we expected. ...If a company does not enter nanotechnology now, in five years, it will be too late..." Mihail Roco, head of National Nanotechnology Initiative at the National Science Foundation.

"The best way I can describe it is if you close your eyes and dream. You could never be sick, have all the energy you need, all the water, all the food and no diseases. There is no aspect in the world economy or your personal life that is not assumed to be transformed by this new technology." Pat Mooney, head of the anti-technology activist organization ETC Group.

NGEN k

NGEN sold off a lot yesterday and today. I can't see why that happened? no news I can see anyway

ty sweetheart wishing you the same... xoxoxoxo

feeling fine. i just read that you were not feeling well... wishing you health and wealth and wisdom!

feeling a little better doc.. still haven't gotten my energy back.. how about you dear

u doing ok??

ty hun

NGEN weekly chart this thing has been flatlined for a few days now

NGEN chart maybe worth looking at

MFIC Corporation Subsidiary, Microfluidics, Receives 2007 Nano 50(TM) Technology Award
Tuesday August 28, 2:16 pm ET

NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC - News), an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries announced today that its wholly owned subsidiary, Microfluidics, has been named a technology category winner in the third annual Nanotech Briefs® Nano 50(TM) Awards. Microfluidics received the award for its revolutionary new Microfluidics Reaction Technology (MRT)--a next-generation approach in the production of nanosuspensions to help pharmaceutical and biotechnology companies develop and ultimately manufacture difficult to formulate drugs.

The Nano 50 recognizes the top 50 technologies, products, and innovators that have significantly impacted, or are expected to impact, the state-of-the-art in nanotechnology. The recipients of the Nano 50 awards comprise the innovative people and designs that will move nanotechnology to key mainstream markets. Nano 50 nominations were judged by a panel of nanotechnology experts.

"The advent of MRT could potentially unlock drugs, vaccines and drug delivery systems that to date could not be formulated," said Dr. Thomai Panagiotou, Vice President of Research and Development at Microfluidics and head of the Company's MRT program. "MRT provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader. We anticipate introducing a new line of equipment to facilitate the MRT process late in the fourth quarter of this year or early in the first quarter of 2008, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics."

About Microfluidics Reaction Technology (MRT):

MRT enables the manufacture of nanosuspensions in a "bottom up" fashion, utilizing chemical reactions and physical processes like crystallization. It has been proven effective for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in a more efficient, cost-effective manner. Conventional "top down" processes can reduce particle sizes, often to the nano-level, through a process of wet-milling, homogenization, micronization, and other techniques. However, there is an absolute limit as to how small top-down processes can reduce particle sizes and it often requires considerable effort, energy and repetitive processing cycles to achieve these levels of reduction.

MRT works by pumping liquid reactants to a Microfluidizer® processor reaction chamber, which is based on impinging jet principals. The system provides precise control of the feed rate and mixing location and has been demonstrated to be more effective in producing nanosuspensions than standard, top-down particle size reducing methods. This process is exceptional for a broad range of applications that require either fast or slow chemical reactions.

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Forward Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.



Contact:
MFIC Corporation
Jack M. Swig, 617-969-5452
info@mfics.com
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
scavanaugh@macbiocom.com

--------------------------------------------------------------------------------
Source: MFIC Corporation

SOTK Form 8-K for SONO-TEK CORP
21-Aug-2007

Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Stat

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 16, 2007, Sono-Tek Corporation (the "Company') announced that Dr. Joseph Riemer will become President of the Company effective September 1, 2007. Dr. Riemer holds a Ph.D. in Food Science and Technology from the Massachusetts Institute of Technology (MIT). Dr. Riemer joined the Company in January 2007 as VP of Engineering, with responsibility for developing a new business segment for the Company in the food industry. Prior to joining the Company, from 2001 to 2006, Dr. Riemer was the Principal of JR Consulting, a management consulting firm, specializing in the areas of Technology Transfer, Research and Development, Engineering and serving clients in the food, biotech and pharmaceutical industries. Dr. Riemer has also held leading positions with several food, food ingredients, and personal care products companies, including 7 years with the Adams Confectionary division of Pfizer where he was Director, Global Operations Development. In addition, Dr. Riemer was appointed to the Board of Directors effective August 16, 2007.

Effective September 1, 2007, Dr. Christopher L. Coccio will relinquish his duties as President and continue in his position as Chief Executive Officer. On August 16, 2007, Dr. Coccio was named Chairman of the Board of Directors, and Samuel Schwartz was named Chairman Emeritus.

Sono-Tek Holds Annual Shareholder Meeting
Friday August 17, 2:07 pm ET

MILTON, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- Sono-Tek Corporation (OTC Bulletin Board: SOTK - News) held its Annual Shareholders Meeting on August 16, 2007 in Milton, New York. The results of Fiscal Year 2007, which ended on February 28, 2007, were reported. During the meeting, Dr. Christopher L. Coccio, President and CEO, described Sono-Tek's continued efforts aimed at developing both new geographical markets and new technology and application based markets.

A multi-year review was presented that showed the Company's progress over the past six years. Highlights included the doubling of sales to nearly $7 million over that period, the increase in sales overseas and to the medical device coating market, the continued emphasis on increasing the talent and manpower in sales, engineering, and service organizations, the reduction in debt to negligible levels, and the increase in shareholder equity and cash reserves to record levels. The past year was noted to be flat in sales due to the electronics segment slowdown. The net income was lower than the previous year due to the addition of key staff and investments in development programs aimed at future growth for the business.

Speaking of the current fiscal year, Dr. Coccio noted that, "Sono-Tek has reported a slowdown in sales in the first quarter, but we expect to see some improvement in the current quarter. We feel we have the financial base, people and programs in place to create the future growth of the Company in the quarters ahead."

New products and applications were also highlighted, such as the entry into alternative energy related coating applications for solar and fuel cells, and an increase in the medical device coating product line to include a peripheral vascular stent coater and a high volume coronary stent coater. New markets include food industry coatings for packaging and food product antimicrobial applications, and the introduction of the SonoDry family of ultrasonic spray dryers for laboratory and nanotechnology applications.

The Company's Board of Directors met subsequent to the annual meeting. At this meeting, Dr. Coccio was named Chairman and Chief Executive Officer in recognition of his contributions over the past six years. The Board named Samuel Schwartz, Chairman Emeritus, and thanked him for his guidance and business judgment over his many years of service and contributions to the Company as Chairman.

Dr. Joseph Riemer, previously VP-Engineering was named President with Sales, Manufacturing, and Technical Services reporting to him, effective September 1, 2007. Dr. Riemer was also appointed to the Board of Directors. He spoke at the meeting about the developing opportunities in the food industry, and will continue to lead our efforts in this exciting market in his role as President.

It was also noted with sadness, that Dr. Harvey Berger, the founder of Sono-Tek and inventor of the ultrasonic atomizing nozzle, passed away on August 9, 2007 after a long illness. Dr. Berger will be remembered by those who worked with him as a mentor and teacher for the younger technical staff at Sono-Tek, as well as a long serving Director, Officer, and friend.

For further information, contact Dr. Christopher L. Coccio, at 845-795-2020, or visit our website at www.sono-tek.com. The Company's slide show presentation used at the annual meeting will be available on the Company's website.

Sono-Tek Corporation is a leading developer and manufacturer of liquid spray products based on its proprietary ultrasonic nozzle technology. Founded in 1975, the Company's products have long been recognized for their performance, quality, and reliability.

This earnings release contains forward looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions; political, regulatory, competitive and technological developments affecting the Company's operations or the demand for its products; timely development and market acceptance of new products; adequacy of financing; capacity additions and the ability to enforce patents. We refer you to documents that the company files with the Securities and Exchange Commission, which includes Form 10-KSB and Form 10-QSBs containing additional important information.

Source: Sono-Tek Corporation

SOTK mentioned favorably in nanotech food article:

http://www.ifi-online.com/Tmpl_Article.asp?contentType=3&ContentID=225

Nanotech firm files for IPO
By Mike Hughlett
Chicago Tribune staff reporter

Nanosphere Inc., a pioneering Northbrook-based nanotechnology firm, Monday filed for an initial public stock offering, intending to raise up to $100 million.

Nanosphere makes a genetic-testing system, and is developing diagnostic tests for a variety of medical conditions, including cancer, cardiovascular and neurodegenerative diseases.

Current genetic testing techniques are complex and are usually performed only at specialized labs or academic research centers. Nanosphere is aiming to commercialize a low-cost testing system that would be sold to hospitals.

The company plans to use about $50 million from the offering to finance research and to develop its product manufacturing, according to a filing Monday with the Securities and Exchange Commission. Another $40 million would be earmarked for marketing, while any remaining money would be used for working capital and other general costs.

Founded nine years ago, Nanopshere has raised over $100 million in private money, including a $57 million venture capital investment last year from a group led by Boston-based Bain Capital. Chicago-based Lurie Investments, Nanosphere's founding investor, is a major shareholder in the company.

So far, Nanosphere's revenues, which were just over $1 million last year, have come primarily from research contracts and government grants, with "minimal" sales stemming from its actual genetic testing system, according to its securities filing.

The firm's future revenues and any profits, which it doesn't have now depend on getting regulatory approval for its testing systems and then commercializing them, the filing said.

Underwriters for Nanosphere's planned IPO are: Credit Suisse, Piper Jaffray, Leerink Swann & Co. and Allen & Co.

Copyright © 2007, Chicago Tribune

Nanotech's influence on the food industry:

http://www.azonano.com/news.asp?newsID=4672

Spray coater protects against contamination
By Ahmed ElAmin
FoodProductionDaily.com
July 27, 2007

A new spray coater can protect foods from becoming contaminated by pathogens, according to its manufacturer.

Sono-Tek's pilot plant scale Universal Food Coater features six independently controlled, ultrasonic atomising nozzles.

The coater can be used to provide anti-microbial protection of baked goods, produce, dairy, meat products. It can also be used to apply nutriceuticals, herbal extracts, and natural flavours directly on to food surfaces, the company stated.

The nozzles are non-clogging and allow a complete 360° coverage of the food target, the company claimed.

This new versatile equipment was developed in response to specific requests from food manufacturers that observed the advantages of Sono-Tek's uniform, low flow, ultrasonic spraying capabilities at our laboratory in a batch mode," the company stated. "These manufacturers are interested in investigating further these benefits in a continuous, pilot plant scale manufacturing capacity."

The unit comes with a variable width, variable speed conveyor, allowing processors to conduct tests in-line with other manufacturing equipment.

The features make the Universal Food Coater suitable for research and development and for those with small production needs.

Christopher Coccio, president and chief executive of Sono-Tek said the machine can help processors achieve uniform, low dose coating, which is of particular importance in the food and pharmaceutical industries.

BIPH moving up past few days. Anyone know why?

#msg-21461541

Nucryst's Nanocrystal Coup
The Motley Fool
July 20, 2007
By Jack Uldrich

What a day for nanocrystals. Earlier today, I penned an article outlining how Nanosys' new nanocrystal metal technology could benefit Harris & Harris (Nasdaq: TINY). No sooner had I finished than I learned that late yesterday, the Food and Drug Administration had granted clearance for Nucryst's (Nasdaq: NCST) prescription topical cream, which contains the company's patent-protected nanocrystalline silver. That has sent shares of this small company up over 150% today.

The cream that was approved utilizes NPI 32101, which is the same technology that failed phase 2 FDA clinical trials back in the fall of 2006, when the regulatory agency determined that it wasn't effective as an anti-inflammatory for dermatitis.

The difference this time is that the cream's antimicrobial properties have been proven effective in creating an anti-microbial barrier against organisms that often cause serious infections in wound and burn victims, as well as those suffering from urinary tract infections.

It's important to understand that the market for antimicrobial applications is not nearly as large as that for dermatitis -- an ailment that afflicts an estimated 15 million Americans. Investors will want to temper their expectations accordingly. It's also important for investors to understand that while the cream has been approved, Nucryst officials have not yet unveiled any details on the product's release. In other words, it could be some time before the cream begins generating revenue for the company.

All things being equal, though, this is a very positive development because it will add a new product line to complement the company's Acticoat wound dressing lineup, which is marketed by Smith & Nephew (NYSE: SNN). But for investors who missed today's pop, I would advise holding off jumping on the bandwagon until the company releases more details about its plans to commercialize on this opportunity.

Interested in reading more about Nucryst? Check out these other articles:

Nucryst IPO Could Burn Investors
Nucryst Still Licking its Wounds
Harris & Harris is a Motley Fool Rule Breakers recommendation.

Fool contributor Jack Uldrich owns stock in Harris & Harris. The Fool has a strict disclosure policy.

Alert Triggered for MTS Systems Corp.
MTSC Reached a New 52 Week High at $46.98

MTSC rose 4.2% to a new 52 week high of $46.98. During the last 52 weeks, MTSC's price has ranged from $30.86 on September 22, 2006 to today's high of $46.98.

Additionally, over the last 12 months, MTSC has increased 37.38%.

Please note you will receive only one "New 52 Week High" alert per day for MTS Systems Corp.

Microfluidics Introduces Basic “No Frills” Microfluidizer Processors for Biopharm Industry

Ideal for Pilot Production of Clinical Batches Requiring cGMP - Enhancements Available When Needed

NEWTON, Mass., July 16, 2007 – Microfluidics has introduced a basic M-700 series of Microfluidizer® high-shear fluid processors ideally suited for producing clinical batches and for scaling up to biopharmaceutical pilot production.

The well established M-7125 and M-7250 machines can now be purchased as economical basic standard biopharmaceutical packages, which include a skid mounted pharma-grade feed pump, a sanitary flush diaphragm pressure transducer with digital readout, and written certifications that all product contact surfaces within the machine and feed pump have been passivated, electro-polished and ground to a 20Ra surface finish.

In keeping with cGMP guidelines, each machine comes standard with IQ/OQ documentation, a document turnover package, on-site start-up and training and CE compliance.

As products evolve, myriad options are available that afford flexibility to the Basic package user. Options can be ordered if or when needed. These include pharma-grade heat exchangers, PLC control, temperature sensing with digital readouts, Ultra Clean In Place (UCIP), and motor starter panels.

Coupled with its patented fixed geometry interaction chambers, the M-700 series Microfluidizer processors generate a controlled rate of shear which allows bacterial, plant and mammalian cells to be safely and efficiently disrupted while enabling the highest shear rates of any fluid processor on the market today to achieve the desired product quality for nano-emulsions and nano-dispersions in the least number of passes.

About Microfluidics

Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. Microfluidics is a leader in innovative technology and comprehensive solutions for formulations requiring repeatability and for the production of uniformly distributed nanoparticles.

Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the Biotechnology and Pharmaceutical industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email mixinginfo@mfics.com or contact Microfluidics at 800.370.5452 for application information.

CONTACT:
Lauren Purpura
Gray & Rice Public Relations
617-367-0100 ext. 123
lpurpura@gr2000.com

Downloads
20070716-1912-0C275321.jpg

SOTK .93 X .98 Food Coating Equipment News:

Sono-Tek Offers New Ultrasonic Spray Coater for Food R&D
Monday July 16, 2:53 pm ET

MILTON, N.Y., July 16 /PRNewswire-FirstCall/ -- Sono-Tek Corporation (OTC BB: SOTK - News), announced today the release of a new pilot plant scale Ultrasonic Spray Coating System - The Universal Food Coater.

This new versatile equipment was developed in response to specific requests from food manufacturers that observed the advantages of Sono-Tek's uniform, low flow, ultrasonic spraying capabilities at our laboratory in a batch mode. These manufacturers are interested in investigating further these benefits in a continuous, pilot plant scale manufacturing capacity.

The Sono-Tek Universal Food Coater is equipped with six independently controlled non-clogging ultrasonic atomizing nozzles, mounted in a fashion allowing complete 360 degree coverage of the food target, at a range of liquid flow rates. The unit is equipped with a variable width, variable speed conveyor, allowing the flexibility for testing independently and/or in-line with other manufacturing equipment. These features make the system ideal for optimization of low flow spray coating processes for R&D and small production capacity needs.

The Universal Food Coater is of particular importance to Product and Process developers in the areas of Anti-Microbial protection of Baked Goods, Fresh Cut produce, Dairy and Meat products, and for the application of low dose nutriceuticals, herbal extracts and natural flavors directly onto the surface of food products.

The unit provides an important R&D tool also for other industries, where in-line, continuous and uniform coating of expensive materials is of significance (e.g. Electronics, Medical Devices and Specialty Chemicals).

According to Dr. Christopher L. Coccio, President and CEO, "In the last 6 months Sono-Tek invested significant resources in introducing our technology to the Food Industry. The launch of our Universal Food Coater will help our customers achieve the benefits of uniform, low dose coating, which is of particular importance with some highly potent actives applications in the food and pharmaceutical industries. Our VP of Engineering, Dr. Joseph Riemer, will be available later this month at the annual meeting of the IFT (Institute of Food Technologists) in Chicago, IL, to discuss specific projects to be conducted either at our laboratory or at customers R&D Centers".

More information on the new Universal Food Coater can be found by contacting Dr. Joseph Riemer at 845-795-2020 or by submitting a query on our website: http://www.sono-tek.com

Sono-Tek Corporation is a leading developer and manufacturer of liquid spray products based on its proprietary ultrasonic nozzle technology. Founded in 1975, the Company's products have long been recognized for their performance, quality and reliability.

This press release contains forward looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions; political, regulatory, competitive and technological developments affecting the Company's operations or the demand for its products; timely development and market acceptance of new products; adequacy of financing; capacity additions and the ability to enforce patents. We refer you to documents that the company files with the Securities and Exchange Commission, which includes Form 10-KSB and Form 10-QSBs containing additional important information.

Source: Sono-Tek Corporation

Thailand : Textile industry goes the nanotech way
July 13, 2007

As part of their effort to write a new chapter in innovative technology, Thailand Textile Institute has entered into a partnership with the National Nanotechnology Centre to come up with new products and production processes.

According to institute's Executive Director Virat Tandaechanurat, the partnership will help the institute widen its technological development for commercial use while allowing local textile manufacturers to develop a broader variety of products.

"We are trying to educate manufacturers associated with Thailand Textile Institute. National Nanotechnology Centre experts can guide them to pay more attention to innovative technology in textile industry," Tandaechanurat told Fibre2fashion.

To begin with, Tandaechanurat said the institute is exploring textile technology to give conventional textiles new properties. One example of this is using nanotechnology to give an anti-bacterial features to fabrics.

Some textile manufacturers have coated fabrics with silver nano particles, which have sterilizing properties, to give it anti-bacterial value. Tandaechanurat said with the help of nanotechnology experts, the country's textile institute is carrying out experiments on how titanium dioxide or zinc oxide can be utilized to developed functional textiles.

Titanium dioxide has self-cleaning properties that can keep clothes spotless while zinc oxide can kill microbes and bacteria. Meanwhile, the institute plans to carry out research on how to ensure that textiles maintain their new features for as long as possible. Currently, nano properties given to textiles last only till 30-50 machine washes.

Tandaechanurat said the institute hopes to apply technology developments discovered through this collaboration to three groups of textiles — fashion textiles, home furnishing textiles and technical textiles, such as fabric used by carmakers.

Fibre2fashion News Desk, India

MFIC News:

Microfluidics To Showcase M-700 Microfluidizer Processor At Chem Show 2007
Source: chemicalonline.com
July 13, 2007

Newton, MA - Microfluidics will showcase the latest version of its laboratory model M-700 Microfluidizer high-shear fluid processor at the Chem Show 2007 Process Equipment & Technology Exhibition, from October 30- November 1 in New York, N.Y. The M-700 series offers pilot and production performance levels with specific features ideally suited for the industrial chemical processing of materials including coatings, waxes, inks, pigments, and sealants.

Allowing for potentially full integration and connectivity to customer SCADA or DCS systems using Microfluidics controls, the M-700 processors are capable of generating up to 40,000 psi for premium results at an affordable cost. Microfluidics guarantees scale-up from laboratory or pilot scale machines to full production machines.

The system is easy to operate and is designed for Ultra Clean In Place (UCIP). The series is also available with Ethernet communication, which connects with the customers factory automation systems.

SOURCE: Microfluidics

MFIC to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Tuesday July 10, 7:00 pm ET

NEWTON, Mass.--(BUSINESS WIRE)--(OTCBB: MFIC - News): MFIC Corporation (MFIC or the Company) announced that the Company will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference at the Mandarin Oriental Hotel in New York City on July 11, 2007 at 4:30 p.m. Eastern Time. Jack Swig, Vice President of Corporate Development and General Counsel, will provide an overview of the Company, review key research and development accomplishments and discuss upcoming corporate initiatives. A link to a live webcast of the presentation will be available on the home page of the Company's website, www.mficcorp.com. A replay of the presentation will be available for 90 days after the conference.

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Contact:
MFIC Corporation
Jack M. Swig, 617-969-5452
info@mfics.com
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
scavanaugh@macbiocom.com

--------------------------------------------------------------------------------
Source: MFIC Corporation

Alert Triggered for MTS Systems Corp.
MTSC Reached a New 52 Week High at $46.85

MTSC rose 0.5% to a new 52 week high of $46.85. During the last 52 weeks, MTSC's price has ranged from $30.75 on September 22, 2006 to today's high of $46.85.

CVD Equipment Corporation Announces Proposed Public Offering of Common Stock
Tuesday July 3, 4:01 pm ET

RONKONKOMA, N.Y., July 3 /PRNewswire-FirstCall/ -- CVD Equipment Corporation (Amex: CVV - News), a designer and manufacturer of state-of-the-art equipment used in the development, design and manufacture of advanced electronic components, materials and coatings for research and industrial applications, announced today that it plans to offer up to 2,500,000 shares of its common stock in a registered public offering through C.E. Unterberg, Towbin, as the managing underwriter. This amount does not include shares that may be sold by certain officers and directors to cover the over-allotment, if any. CVD Equipment Corporation intends to use the proceeds from the offering for general corporate purposes, including, but not limited to, possible future product development efforts, acquisitions, or strategic alliances.

A registration statement relating to the common stock has been filed with the Securities and Exchange Commission but has not yet become effective. The shares of common stock may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. There can be no assurance that CVD Equipment Corporation will complete the offering on the anticipated terms, or at all. CVD Equipment Corporation's offering and its business are subject to risks described in the company's filings with the Securities and Exchange Commission.

This disclosure does not constitute an offer to sell or the solicitation of an offer to buy any of CVD Equipment Corporation's securities, nor will there be any sale of these securities by CVD Equipment Corporation in any jurisdiction in which the offer, solicitation or sale would be unlawful. A written prospectus for the offering may be obtained by contacting the company at the address set forth below.

About CVD Equipment Corporation

CVD Equipment Corporation (Amex: CVV - News) is a designer and manufacturer of state-of-the-art equipment used in the development, design and manufacture of advanced electronic components, materials and coatings for research and industrial applications. We offer a broad range of chemical vapor deposition, gas control, and other equipment that is used by our customers to research, design and manufacture semiconductors, solar cells, carbon nanotubes, nanowires, LEDs, MEMS, and equipment for surface mounting of components onto printed circuit boards.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by CVD Equipment Corporation) contains statements that are forward-looking. All statements other than statements of historical fact are hereby identified as "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward looking information involves a number of known and unknown risks and uncertainties that could cause actual results to differ materially from those discussed or anticipated by management. Potential risks and uncertainties include, among other factors, industry specific and general business conditions, competitive market conditions, success of CVD Equipment Corporation's growth and sales strategies, the possibility of customer changes in delivery schedules, cancellation of orders, potential delays in product shipments, delays in obtaining inventory parts from suppliers, failure to satisfy customer acceptance requirements and other risk factors described in CVD Equipment Corporation's SEC filings. All forward-looking statements are based on management's estimates, projections and assumptions as of the date hereof and CVD Equipment Corporation assumes no obligation to update this press release.

--------------------------------------------------------------------------------
Source: CVD Equipment Corporation

Alert Triggered for MTS Systems Corp.
MTSC Reached a New 52 Week High at $46.30

MTSC rose to a new 52 week high of $46.30. During the last 52 weeks, MTSC's price has ranged from $30.75 on September 22, 2006 to today's high of $46.30.

Microfluidics Unveils New Technology Center
PharmacueticalOnline.com
June 29, 2007

Microfluidics, a wholly owned subsidiary of MFIC Corporation, has announced the opening of the Microfluidics Technology Center, a state-of-the-art research and discovery facility. Located at the Microfluidics company headquarters in Newton, Mass., the Center was officially unveiled during the company’s annual shareholders meeting on June 21. Microfluidics President and COO, Bob Bruno, delivered an overview of the company’s rich heritage and provided guests with a scope of what the Center will bring to existing and potential customers in the biotech, pharmaceutical, chemical, personal care and food industries.

“The opening of the Center demonstrates our ongoing commitment to advancing the fluid processing industry and to providing the highest quality of service to our customers,” said Bruno. “While we have always worked closely with customers to solve their most challenging formulation problems, the Microfluidics Technology Center will maximize this experience by providing access to leading R&D engineers and the most advanced equipment in a single-laboratory setting designed specifically with our customers’ unique needs in mind.”

Microfluidics is an industry leader in materials processing and formulation equipment, and possesses the unique ability to produce the most uniform and smallest liquid and suspended structures available for the biotech, pharmaceutical, chemical, personal care and food industries. The Microfluidics Technology Center will provide customers full access to the company’s R&D engineers and complete product suite to prepare, characterize and optimize formulation samples. Engineers will also assist customers in improving existing products through reformulation using proprietary, leading-edge, high-shear Microfluidizer® processors.

“The Microfluidics Technology Center will house our highly-specialized research team, dedicated to advancing the formulation field by developing new applications for Microfluidics’ technology and pursuing groundbreaking work in the field of nanotechnology,” said Dr. Thomai Panagiotou, vice president of research and development.

“We are very excited about the Center and believe it will serve as an innovation hub, playing a critical role in unlocking countless formulation solutions for our customers—including potentially life-saving drugs—that to date could not be formulated.”

Acting Chairman James Little provided Dr. Panagiotou with the keys to the Center and presented founder and former CEO and Chairman, Irwin J. Gruverman, with a plaque commemorating his 25 years of service with the company.

About Microfluidics

Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the Biotechnology and Pharmaceutical industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, e-mail <"mailto: mixinginfo@mfics.com">mixinginfo@mfics.com or contact Microfluidics at (800) 370-5452 for application information.

SOTK had already guided weaker sales for Q1 from their electronics business which has been de-emphasized due to overseas competition. This is what has led to a big transformation of the company and a major diversification program.

What I liked in the 10-Q was:

-the higher sales of stent coating equipment which should start to accelerate now that all of the big medical device makers are introducing next-generation drug coated stents;

-higher WideTrack equipment sales which are being applied to coatings for glass, textiles, plastic, metal, food products and packaging materials;

-and the uptick in the gross profit margin to 49% from 46.5%.

http://biz.yahoo.com/e/070622/sotk.ob10qsb.html

Alert Triggered for MFIC Corp.
MFIC Corp. (MFIC) Price Crossed Above Its 60 Day Moving Average

MFIC crossed above its 60 day moving average of $1.71 with a trade of $1.77 at 3:07 PM EDT, up 3.5% from the moving average. It is currently trading higher on the day, up 2.3% to $1.75.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for MFIC.

MFIC Announces Opening of Microfluidics Technology Center
Thursday June 21, 7:00 am ET
Innovation Hub Dedicated to Advancing the Micro- and Nano-Formulation Fields

NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (MFIC or the Company)(OTCBB: MFIC - News) today announced the opening of the Microfluidics Technology Center, a state-of-the-art research and discovery facility located at the MFIC company headquarters in Newton, MA. MFIC is an industry-leader in fluid formulation processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.

"The Microfluidics Technology Center will house our highly-specialized research team, dedicated to advancing the formulation field by developing new applications for Microfluidics' technology and pursuing groundbreaking work in the field of nanotechnology," said Dr. Thomai Panagiotou, Vice President of Research and Development. "We are very excited about the Center and believe it will serve as an innovation hub, playing a critical role in unlocking countless formulation solutions for our customers--including potentially life-saving drugs--that to date could not be formulated."

The Microfluidics Technology Center will provide customers full access to the Company's R&D engineers and complete product suite to prepare, characterize and optimize formulation samples. Engineers will also assist customers in improving their existing products through reformulation using proprietary, leading-edge, high-shear Microfluidizer® materials processors.

"The opening of the Center demonstrates our ongoing commitment to advancing the industry and to providing the highest quality of service to our customers," said Bob Bruno, President and Chief Operating Officer. "While we have always worked closely with customers to solve their most challenging formulation problems, the Microfluidics Technology Center will maximize this experience by providing access to the best engineers and the most advanced equipment in a single-laboratory setting designed specifically with our customers' unique needs in mind."

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Forward Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.



Contact:
MFIC Corporation
Jack M. Swig, 617-969-5452
info@mfics.com
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
scavanaugh@macbiocom.com

--------------------------------------------------------------------------------
Source: MFIC Corporation

BEFORE THE BELL: -2-
9:03 AM EDT June 20, 2007

Luna Innovation Up After Reporting Nano Study

Shares of Luna Innovation Inc. (LUNA) rose 12% to $5.30 after the company reported its researchers showed in a study that nanospheres were able to block an allergic response to human cell cultures experiments and mice.

The company said it was seeking pharmaceutical partnerships to develop and validate the nano-sized compounds.
Luna collaborated with Virginia Commonwealth University in the study.

Nanoparticle Offers Promise For Treating Glaucoma
Science Daily
Source: University of Central Florida
Date: June 19, 2007

A unique nanoparticle made in a laboratory at the University of Central Florida is proving promising as a drug delivery device for treating glaucoma, an eye disease that can cause blindness and affects millions of people worldwide.

“The nanoparticle can safely get past the blood-brain barrier making it an effective non-toxic tool for drug delivery,” said Sudipta Seal, an engineering professor with appointments in UCF’s Advanced Materials Processing and Analysis Center and the Nanoscience Technology Center.

Seal and his colleagues from North Dakota State University note in the article that while barely 1-3 percent of existing glaucoma medicines penetrate into the eye, earlier experiments with nanoparticles have shown not only high penetration rates but also little patient discomfort. The miniscule size of the nanoparticles makes them less abrasive than some of the complex polymers now used in most eye drops.

Seal and his team created a specialized cerium oxide nanoparticle and bound it with a compound that has been shown to block the activity of an enzyme (hCAII) believed to play a central role in causing glaucoma.

The disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss. High pressure occurs, in part, because of a buildup of carbon dioxide inside the eye, and the compound blocks the enzyme that produces carbon dioxide.

Seal and a team of collaborators including Sanku Mallik, of North Dakota State University, developed the research on using nanoparticles as a delivery mechanism for the compound after supervising a student summer project at UCF. Duke University undergraduate Serge Reshetnikov spent a summer studying nanoscience on UCF’s Orlando campus as part of a Research Experience for Undergraduates (REU) project funded by the National Science Foundation. Reshetnikov started looking into the possibilities of using nanoparticles as drug delivery tools. Subsequent research with his advisors led to the specific application for glaucoma.

In their paper on the research, which was also supported by the National Science Foundation, Seal and Mallik note the results are “very promising” and that their nanoparticle configuration offers seemingly limitless possibilities as a non-toxic drug delivery tool.

The findings will be published in an article appearing in the June 28 issue of the Journal of Physical Chemistry C.

Note: This story has been adapted from a news release issued by University of Central Florida.

Alert Triggered for Sono Tek Corp.
Sono Tek Corp. (SOTK) Price Crossed Above Its 60 Day Moving Average

SOTK crossed above its 60 day moving average of $1.16 with a trade of $1.20 at 10:04 AM EDT, up 3.4% from the moving average.

Alert Triggered for Uluru Inc
ULUR Reached a New 52 Week High at $5.65

ULUR rose 20.2% to a new 52 week high of $5.65. During the last 52 weeks, ULUR's price has ranged from $0.55 on August 3, 2006 to today's high of $5.65.

SOTK 1.10, 14.4 mil. shs. out. and consistently profitable. All of the big medical device makers are introducing next generation drug coated stents which should pave the way for a resurgence of business for SOTK's stent coating equipment line:

J&J's Cordis unit resolves issues with FDA

CHICAGO, June 14 (Reuters) - Johnson & Johnson (JNJ.N: Quote, Profile , Research) on Thursday said its Cordis unit, which makes cardiovascular devices, has resolved its issues with the U.S. Food and Drug Administration, clearing the way for the introduction of new products.

Cordis, best known for its Cypher drug-eluting heart stent, has been operating under a warning from the FDA since April 2004. Regulators cited problems with internal procedures, including many issues with manufacturing processes.

Resolving the issues with the FDA means the company can now launch the next-generation of its Cypher stent, a tiny, tubular device that props open diseased arteries and delivers drugs to the site to prevent the vessels from reclogging.

Cordis' Cypher stent competes in the United States with Boston Scientific's (BSX.N: Quote, Profile , Research) Taxus drug-eluting stent. Medtronic Inc. (MDT.N: Quote, Profile , Research) and Abbott Laboratories (ABT.N: Quote, Profile , Research) are expected to launch similar products in the United States over the next few years.

However, the use of such devices, initially hailed as revolutionary, has declined over the last few quarters amid controversy that they may pose serious risks of deadly blood clots.

And drug-eluting stents, which have been lucrative for the manufacturers, came under fire when a study suggested the devices were no better than standard drug treatments in reducing deaths and heart attacks in patients with minor chest pain.

Miami Lakes, Florida-based Cordis said the penetration of drug-eluting stents, also known as drug-coated stents, was down to the mid-60 percent range as of April from a peak in the mid-80 percent range a few years ago.

J&J shares were up 9 cents to $62.27 while shares of competitor Boston Scientific were up 2 cents to $16.16 in early the New York Stock Exchange trade.

MFIC 1.68 - New nanotechnology center news:

Microfluidics expands in Newton
BostonGlobe.com
By Chris Reidy, Globe staff
Thursday, June 14, 2007

Microfluidics Corp. will unveil a new technology center in its home town of Newton next week.

The company specializes in Microfluidizer processors that are used in reseach-and-development laboratories as well as in pilot and production manufacturing operations; the company said its equipment enables the manufacture and formulation of numerous nano-materials and nano-scale products in the pharmaceutical, biotechnology, chemical, cosmetic, and food industries.

The center will house state-of-the-art technology and enable Microfluidics application specialists to enhance their work with potential customers to prepare physical samples, documentation, microscopic digital images, and particle-sized analysis of improved processes, the company said.

Posted by Boston Globe Business Team at 08:00 AM

Researchers Develop New Nanomaterials to Deliver Anticancer Drugs to Cells

Researchers at UCLA have successfully manipulated nanomaterials to create a new drug-delivery system that promises to solve the challenge of the poor water solubility of today's most promising anticancer drugs and thereby increase their effectiveness.

The poor solubility of anticancer drugs is one of the major problems in cancer therapy because the drugs require the addition of solvents in order to be easily absorbed into cancer cells. Unfortunately, these solvents not only dilute the potency of the drugs but create toxicity as well.

In a paper scheduled to be published in the nanoscience journal Small in June, researchers from UCLA's California NanoSystems Institute and Jonsson Cancer Center report a novel approach using silica-based nanoparticles to deliver the anticancer drug camptothecin and other water-insoluble drugs into human cancer cells.

The study is led by Fuyu Tamanoi, UCLA professor of microbiology, immunology and molecular genetics and director of the Jonsson Cancer Center's Signal Transduction and Therapeutics Program Area, and Jeffrey Zink, UCLA professor of chemistry and biochemistry.

Tamanoi and Zink devised a method for incorporating the representative hydrophobic anticancer drug camptothecin into the pores of fluorescent mesoporous silica nanoparticles and delivering the particles into a variety of human cancer cells to induce cell death. The results suggest that the mesoporous silica nanoparticles might be used as a vehicle to overcome the insolubility problem of many anticancer drugs.

"Silica nanomaterials show promise for delivering camptothecin and other water-insoluble drugs," Tamanoi said. "We have successfully loaded hydrophobic anticancer drugs into mesoporous nanoparticles and delivered them into human cancer cells to induce cell death."

"The beauty of our findings is that these nanoparticles are biocompatible, contain tubular pores and are relatively easy to modify," Zink said. "Additional modification by attaching a
ligand against a cancer-cell-specific receptor can make the nanoparticles recognizable by cancer cells."

A critical obstacle and challenge for cancer therapy is the limited availability of effective biocompatible delivery systems. Since many effective anticancer agents have poor water solubility, the development of novel delivery systems for these molecules without the use of organic solvents has received significant attention.

Camptothecin (CPT) and its derivatives are considered to be among the most effective anticancer drugs of the 21st century. Although studies have demonstrated their effectiveness against carcinomas of the stomach, colon, neck and bladder, as well as against breast cancer, small-cell lung cancer and leukemia in vitro, clinical application of CPT in humans has only been carried out with CPT derivatives that have improved water solubility.

"In order to be used on humans, current cancer therapies such as CPT or Taxol, which are poorly water soluble, must be mixed with organic solvents in order to be delivered into the body," Tamanoi said. "These elements produce toxic side effects and in fact decrease the potency of the cancer therapy."

To overcome these problems, drug delivery systems using pegylated polymers, liposomal particles or albumin-based nanoparticles have been developed.

The new research findings show that mesoporous silica nanoparticles offer great potential and a promising approach to the delivery of therapeutic agents into targeted organs or cells. The pores in the nanoparticles could be closed by constructing an appropriate cap structure. This provides the ability to control the release of anticancer drugs by external stimuli.

The research was supported by grants from the National Institutes of Health and the National Science Foundation and represents a collaboration between two totally different fields: bioscience and chemistry. The researchers came together because of their common interests in the identification of novel anticancer drugs and the potential for nano-delivery. Both Tamanoi and Zink are members of the California NanoSystems Institute at UCLA, which encourages cross-disciplinary collaboration to solve problems in nanoscience and nanotechnology.

For information about Fuyu Tamanoi's research, visit the Tamanoi Research Lab's Web site at www.mimg.ucla.edu/faculty/tamanoi.

For more information about Jeffrey Zink, visit the Zink Group Web site at www.chem.ucla.edu/dept/Faculty/zink/index.php.

About the California NanoSystems Institute
The California NanoSystems Institute (CNSI) is a multidisciplinary research center at UCLA whose mission is to encourage university-industry collaboration and to enable the rapid commercialization of discoveries in nanosystems. CNSI members include some of the world's preeminent scientists, and the work conducted at the institute represents world-class expertise in five targeted areas of nanosystems-related research: renewable energy; environmental
nanotechnology and nanotoxicology; nanobiotechnology and biomaterials; nanomechanical and nanofluidic systems; and nanoelectronics, photonics and architectonics. For additional information, visit the CNSI Web site at www.cnsi.ucla.edu.

About UCLA
UCLA is California's largest university, with an enrollment of nearly 37,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 300 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.

Wednesday, June 06, 2007
University of California Los Angeles

Media Contacts:
Kim Irwin
(310) 206-2805
(310) 794-0777
kirwin@support.ucla.edu

Additional Resources:
Jennifer Marcus
UCLA
(310) 267-4839
jmarcus@cnsi.ucla.edu

Anybody here following TDON.PK? skidos

SOTK 1.15 - Persistent buying activity in SOTK in the past few days has seen the bid/ask rise to 1.15/1.20 from .91/1.02. SOTK's diverisfication plan into coatings for medical devices, glass, food technology, textiles and nanotech has apparently begun to capture the imagination of investors in this profitable small cap stock with only 14.4 million shares outstanding.